Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial ; volume:40 ; number:10 ; day:19 ; month:8 ; year:2023 ; pages:4626-4638 ; date:10.2023
Advances in therapy ; 40, Heft 10 (19.8.2023), 4626-4638, 10.2023

Creator
McGarvey, November
Ung, Brian
Carattini, Thomas
Imanak, Ken
Lee, Abraham
Campbell, Timothy B.
Patwardhan, Pallavi
Contributor
SpringerLink (Online service)

DOI
10.1007/s12325-023-02623-w
URN
urn:nbn:de:101:1-2023112713155061051510
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • McGarvey, November
  • Ung, Brian
  • Carattini, Thomas
  • Imanak, Ken
  • Lee, Abraham
  • Campbell, Timothy B.
  • Patwardhan, Pallavi
  • SpringerLink (Online service)

Other Objects (12)

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease

Management of relapsed-refractory diffuse large B cell lymphoma

Management of relapsed-refractory diffuse large B cell lymphoma

Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience

Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Related objects